IMO-3100 / Aceragen - LARVOL DELTA

Idera Pharmaceuticals presents data from a multiple-dose phase 1 clinical trial of IMO-3100, lead drug candidate for the treatment of autoimmune diseases (Idera Pharmaceuticals, Inc) - P1, N=24; IMO-3100 was well tolerated in both treatment regimens; Suppression of multiple cytokines including IFN- a, IL-6, MIP-1B, and IL-1Ra, mediated through TLR7 & TLR9 was observed in both IMO-3100 groups

P1 data • Rheumatoid Arthritis

Idera Pharma: BIO CEO & Investor Conference (Idera Pharmaceuticals, Inc) - Anticipated presentation of full P2 proof-of-concept data for psoriasis in Q2 2013

Anticipated P2 data • Psoriasis

Idera Pharmaceuticals reports third quarter 2012 financial results (Idera Pharmaceuticals, Inc) - Anticipated top line P2 data by year-end 2012

Anticipated P2 data • Psoriasis

Idera Pharma: BIO CEO & Investor Conference (Idera Pharmaceuticals, Inc) - "IMO-3100: Proof of Concept Established in Patients with Psoriasis"; "Treatment with IMO-3100 was well tolerated"; "Rapid improvement in Psoriasis Area and Severity Index (PASI) scores in IMO-3100 treated subjects"; "PASI decreased 35% to 90% in half of all IMO-3100 treated patients"; "PASI-50 was achieved in 25% of patients treated with 0.16 mg/kg and in 31% with 0.32 mg/kg"; PASI decrease among patients treated with IMO-3100 at 0.16 mg/kg was statistically significant"; "Significant improvement in plaque induration, a clinical assessment of plaque thickness, at 0.16 mg/kg dose"

P2 data • Psoriasis

Idera Pharmaceuticals announces positive top-line results from phase 2 trial of IMO-3100 in patients with moderate-to-Severe plaque psoriasis (Idera Pharmaceuticals, Inc) - P2a, N=44; NCT01622348; "At the end of the four-week follow-up period, 48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort... (p<0.005)."

P2 data • Psoriasis

Idera Pharma: Annual Report 2013 (Idera Pharmaceuticals, Inc) - Anticipated expiry of patents covering chemical composition of matter and methods of use in 2026

Anticipated patent expiry • Psoriasis

Idera announces presentation of positive data from phase 2 trial of TLR 7 and 9 antagonist in patients with moderate-to-severe plaque psoriasis (Idera Pharmaceuticals, Inc) - P2, N=44; NCT01622348; "48% of patients treated with either dose of IMO-3100 (12 of 25) demonstrated statistically significant improvements of 35% to 90% from baseline PASI scores compared with 0 of 12 in the placebo cohort (p<0.005)...Idera has determined that the next step is to conduct a Phase 2 clinical trial of IMO-8400 in patients with psoriasis...In this trial, 32 patients would be randomized...Idera anticipates initiating enrollment under this protocol during the second quarter of 2013."

Anticipated target enrollment • Anticipated trial initiation date • P2 data • Psoriasis

IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activity in psoriasis patients with 4 weeks of treatment in a phase 2a trial (SID-ESDR-JSID 2013) - Presentation time: Thursday, May 9, 2013; 6:00 PM; Abstract #156; P2a, N=44; NCT01622348; Sponsor: Idera Pharma; "Clinical improvement was sustained, consistent with inhibition of cytokine induction; at Day 57, PASI decreases of 35% to 90% were observed in 12 (48%) of 25 patients treated with IMO-3100 compared with 0 of 12 placebo recipients (p<0.005)."

P2 data • Psoriasis

Idera Pharma: Q4 & FY 2012 Results (Idera Pharmaceuticals, Inc) - Anticipated data from P2 trial for moderate to severe plaque psoriasis at International Investigative Dermatology meeting (May 08-11, 2013)

Anticipated P2 data • Psoriasis

Idera announces clinical development progress in its autoimmune diseases program (Idera Pharmaceuticals, Inc) - P1, N=32; "Idera Pharmaceuticals...completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that its protocol for a Phase 2 study of IMO-8400 in patients with psoriasis has received “no objection” clearance from the Competent Authority of the Netherlands...The Company expects to report top-line data from the multiple-dose portion of the trial later in the second quarter of 2013"; P2, N=44; NCT01622348; "Top-line microarray results of the clinical samples show significant improvement of psoriasis disease-associated gene profile in patients treated with IMO-3100 compared to placebo"

Anticipated new P2 trial • Anticipated P1 data • P2 data • Regulatory • Trial status • Psoriasis

Idera announces presentation at AAD annual meeting demonstrating toll-like receptor antagonists normalize expression of inflammatory genes in psoriasis model (Idera Pharmaceuticals, Inc) - "Idera...announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis...genes related to the production of key mediators of psoriasis including Interleukin (IL) -17, IL-6, IL-12/23, IL-1, IL-21 Receptor, and INF-gamma were restored toward normal levels..." Anticipated presentation of P2 detailed results from the clinical trial at the International Investigative Dermatology Annual Meeting in May 2013; Anticipated P1 data of IMO-8400 in Q2 2013.

Anticipated P1 data • Anticipated P2 data • Preclinical